about
Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity.Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals.CYP3A activity: towards dose adaptation to the individual.No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction Studies.Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B.Use of microdose phenotyping to individualise dosing of patients.Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.Response to "can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?": evaluation of CYP3A activity with microdoses of midazolam.A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.St. John's wort treatment in women bears risks beyond pharmacokinetic drug interactions.Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry.Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing.Normal CYP3A activity during arsenic trioxide therapyImpact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditionsThe first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myelomaA follow-up report on potential drug interactions with clementines: Two single case experiments show no effect on CYP3A-dependent midazolam clearanceSimultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses
P50
Q34635596-0285A927-A101-41CA-AA0B-4F383B0EBB37Q35023726-D9DE850C-7DEF-4242-82DB-63889929E5E4Q35798947-EB7F5107-AA0E-4E3A-9749-57B301A6D40FQ37663461-88F5896B-03C8-454E-B368-5C3A95331CF6Q38763583-9A23406C-894B-4310-A6C2-CF0EA99100B2Q38894543-31302B32-5C2D-480D-A1AB-0C7CF76C7CD9Q39798811-DD25D669-6097-4661-A9BF-2D492A01E851Q39806822-DC8BE486-DABC-4A57-AF22-BEDE14674C2CQ40996401-24F6DD11-3F7E-4EAE-B13B-AD2CAAE82D24Q47425844-9FA78907-7338-40A7-B0FC-A4FE8A0F2536Q47915243-7B6A1876-F4AD-475B-994C-FBAAEF8F598BQ48025123-5CF797A9-6E0E-4AA6-84F4-F8C296249050Q48188509-C92D87AF-F063-4AD2-B8D0-26921E56FA3CQ48194386-BBB4B3E9-9982-42E0-9BD5-E54C6A15E657Q48333024-93594AA8-9AFF-4B15-80FD-E7B30114BDECQ51703757-F229F3FB-378E-4FE7-888E-110764747B5FQ56832232-CA1E5BEC-F993-47D5-88DF-C41249DD13BFQ89494218-CC708509-F6F2-4D08-BD1C-763430B60A31Q92052566-CC7A1D93-8726-4272-A220-869221E973E6Q92579682-EE85F058-05EE-4EB5-9388-5E6DA0408230Q92924697-8D5F714F-DCDF-4CC6-B309-83F4161E4E8C
P50
description
investigador
@es
researcher
@en
name
Nicolas Hohmann
@en
type
label
Nicolas Hohmann
@en
prefLabel
Nicolas Hohmann
@en
P31
P496
0000-0001-8036-8806